Clinical Application and Medical Decision Analysis of TESE/ICSI Technology in Georgia

Medical Logic and Indications for TESE/ICSI Technology

Pathological Basis and Decision-Making Process for TESE Surgery

TESE (Testicular Sperm Extraction) directly answers the core question: whether sperm usable for ICSI exists within the patient's testicles. The starting point of reproductive medical decision-making is to clarify the type of azoospermia. Patients with obstructive azoospermia typically have normal testicular spermatogenic function; sperm are blocked in the seminal ducts, and the sperm retrieval rate via TESE can reach 70%–90%. Patients with non-obstructive azoospermia have intrinsic spermatogenic dysfunction in the testicles, with sperm retrieval rates fluctuating between 30%–60% depending on the etiology.

When determining whether to recommend TESE surgery, physicians need to consider the following indicators:

• No sperm found in at least two semen samples after centrifugation and microscopic examination
• Serum FSH level (more than twice the upper normal limit indicates severely impaired spermatogenesis)
• Testicular volume (less than 8 ml often suggests spermatogenic epithelial atrophy)
• Chromosome karyotype analysis (to rule out genetic abnormalities such as Klinefelter syndrome)
• Y chromosome microdeletion testing (determines surgical strategy and genetic risk)

In clinical practice in Georgia, the above evaluation process is largely consistent with the guidelines of the European Society of Human Reproduction and Embryology (ESHRE). The preoperative evaluation period typically takes 2–4 weeks, with some tests (such as chromosome karyotyping) requiring about 3 weeks for results.

Key Operational Steps of ICSI Technology

ICSI (Intracytoplasmic Sperm Injection) is performed after sperm retrieval via TESE. The procedure involves directly injecting a single sperm into the cytoplasm of a mature oocyte, bypassing the natural fertilization processes of sperm penetration through the zona pellucida and oolemma. The ICSI operational standards adopted by reproductive centers in Georgia are consistent with mainstream global protocols, including:

• Oocyte denudation (usually performed 2–4 hours after oocyte retrieval)
• Sperm immobilization (using PVP solution to reduce sperm motility)
• Micromanipulation needle puncture of the oocyte (with the polar body positioned at 6 or 12 o'clock)
• Post-injection assessment (observing pronucleus formation after 16–18 hours)

The fertilization rate for ICSI is typically 70%–85% and is not significantly affected by the sperm source (ejaculated or testicular sperm). However, the subsequent developmental capacity of the embryo is closely related to sperm quality, oocyte quality, and laboratory culture conditions.

Technical Characteristics of TESE/ICSI in Georgia

Medical System and Laboratory Configuration

Most assisted reproductive laboratories in Georgia are equipped with imported incubators, micromanipulators, and air purification systems, with hardware levels comparable to medium-sized reproductive centers in Europe. TESE surgery is generally performed in an outpatient operating room under local anesthesia or intravenous sedation, with a surgical duration of about 30–60 minutes. Patients can be discharged after 2–4 hours of observation if no abnormalities occur.

Compared to European and American countries, Georgia differs in the following aspects:

• Laboratory quality control system: Some centers use internal quality control standards rather than unified international certifications (e.g., ISO 15189)
• Embryo culture strategy: Tendency to use continuous culture media rather than sequential culture media
• Freezing technology: High prevalence of vitrification; oocyte and embryo survival rates are above 90%
• Genetic testing: PGT (Preimplantation Genetic Testing) requires sample outsourcing, extending the cycle by 1–2 weeks

Legal Environment and Patient Rights

Georgian law permits the legal use of assisted reproductive technologies, including TESE/ICSI, oocyte donation, and third-party assisted reproduction. However, the following matters need to be clarified:

• TESE surgery requires signing an informed consent form, clearly stating the possibility of not retrieving sperm
• Retrieved sperm can be cryopreserved, but the post-thaw survival rate is approximately 40%–60%
• If PGT testing is performed on embryos formed after ICSI, an additional genetic testing consent form must be signed
• Patients have the right to request to view the laboratory's qualifications and the operator's practice license

Clinical Data and Factors Influencing Success Rates

Sperm Retrieval and Fertilization Rates by Etiology

The following data are derived from published clinical studies and industry reports, reflecting population-level data ranges; individual results may vary:

Note: The live birth rate data in the table above are based on the premise of female age under 35 and normal ovarian function. If the female age exceeds 38 or ovarian reserve is diminished, the live birth rate will be further reduced.

Key Variables Affecting ICSI Embryo Development

In addition to sperm source, the following factors significantly influence ICSI outcomes:

• Oocyte maturity: When the proportion of MII oocytes is below 70%, fertilization rates and embryo quality decline
• Sperm DNA fragmentation rate: When DFI exceeds 30%, embryo implantation rates decrease by approximately 15%–20%
• Laboratory culture conditions: Oxygen concentration (5% low oxygen culture is superior to atmospheric oxygen culture), culture media batch variation
• Operator experience: The annual number of micromanipulation procedures performed by the operator is recommended to be over 50 cycles

Key Aspects of Preoperative Evaluation

Chromosomal and Genetic Evaluation

This is the most easily overlooked yet most important evaluation step. Approximately 15% of patients with non-obstructive azoospermia have chromosomal abnormalities or Y chromosome microdeletions. These include:

• Chromosome karyotype analysis: Detects Klinefelter syndrome (47,XXY), autosomal translocations, etc.
• Y chromosome microdeletion testing: Deletions in AZFa, AZFb, AZFc regions; patients with AZFc deletion can retrieve sperm via TESE, but male offspring will inherit the deletion
• CFTR gene mutation screening: Applicable for patients with obstructive azoospermia to rule out congenital bilateral absence of the vas deferens

In Georgia, the above tests can be completed through local or outsourced laboratories. The cost of chromosome karyotype analysis is approximately $200–$400, and Y chromosome microdeletion testing is approximately $300–$500.

Endocrine Evaluation

Hormone levels can indirectly reflect the state of testicular spermatogenic function. The following indicators are of reference value:

• FSH: Above 20 IU/L suggests severely impaired spermatogenesis
• LH: Significantly elevated suggests primary testicular failure
• Testosterone: Below 10 nmol/L may affect intratesticular spermatogenesis
• Inhibin B: Below 40 pg/ml is associated with sperm retrieval failure

The relationship between FSH level and TESE outcome is not absolute. Some patients with elevated FSH can still have sperm retrieved; therefore, the decision to abandon surgery should not be based solely on FSH levels.

Testicular Structure and Function Evaluation

Testicular ultrasound can measure testicular volume, assess blood flow signals, and rule out space-occupying lesions. Magnetic resonance imaging (MRI) is used for locating cryptorchidism or when tumors are suspected. The difference in testicular volume between palpation and ultrasound measurement should not exceed 20%; otherwise, ultrasound measurement error should be considered.

Common Consultation Questions and Medical Explanations

How long does TESE surgery take? How long after surgery is recovery?

The surgery typically takes 30–60 minutes. Mild scrotal swelling and pain may last for 3–7 days postoperatively. It is recommended to rest for 1–2 weeks before resuming normal activities. Avoid strenuous exercise and sexual activity for 4 weeks after surgery. Scrotal hematoma or infection occurs rarely, with an incidence of about 1%–3%.

Can the retrieved sperm be cryopreserved? Does freezing affect ICSI results?

Yes, it can be frozen. The post-thaw survival rate of testicular sperm is about 40%–60%. When used for ICSI, the fertilization rate shows no significant difference compared to fresh sperm (clinical data shows a fertilization rate of 78% for the fresh sperm group and 74% for the frozen group). However, the freeze-thaw process may lead to increased sperm DNA damage, so it is recommended to be performed at experienced centers.

How to choose between ICSI and conventional in vitro fertilization (IVF) in Georgia?

The selection principle is mainly based on sperm parameters:

• Sperm concentration below 5×10⁶/ml, or progressive motility below 10%: ICSI is recommended
• Fertilization rate below 30% in previous IVF cycles: ICSI is recommended
• Use of frozen sperm or testicular sperm: ICSI is mandatory
• Normal sperm parameters and no history of fertilization failure: Conventional IVF can be chosen

In Georgia, the application rate of ICSI is about 60%–70%, higher than in some European countries, which is related to the higher proportion of male infertility factors in the patient population.

Does TESE surgery affect subsequent hormone levels?

The effect of a single TESE surgery on testosterone levels is usually transient. Testosterone levels decrease by about 5%–10% three months post-surgery compared to preoperative levels, but most patients recover to baseline levels within 6–12 months. The risk of cumulative damage increases with multiple or bilateral TESE surgeries; it is recommended to have an interval of at least 6 months between procedures.

Technical Risks and Key Points for Informed Consent

Surgical Risks

• Scrotal hematoma: Incidence about 2%–5%, most resolve spontaneously
• Infection: Incision infection or epididymitis, incidence less than 1%
• Testicular atrophy: Rare, associated with excessive tissue resection or vascular injury
• Chronic scrotal pain: Incidence about 1%–2%

Genetic Risks

The genetic risk of embryos obtained through TESE/ICSI is related to the sperm source and the male's genetic background:

• Y chromosome microdeletion: Male offspring will inherit the deletion 100%
• Klinefelter syndrome: Increased risk of sex chromosome abnormalities in offspring (about 1%–3%)
• Autosomal translocation: Risk of unbalanced chromosome translocation in offspring is about 10%–20%

All patients should complete genetic counseling and sign an informed consent form before undergoing TESE/ICSI. Some reproductive centers in Georgia require genetic counseling records to be documented before entering the treatment cycle.

Embryo Development Risks

ICSI technology itself does not increase the risk of fetal structural malformations, but the rate of chromosomal abnormalities in ICSI offspring is slightly higher than in natural pregnancies (mainly related to paternal genetic factors). Current follow-up data show that the birth defect rate in ICSI offspring is about 2.5%–3.5%, compared to about 2%–3% in natural pregnancies.

Risk Reminder

The core risk of TESE/ICSI technology lies not in the surgical procedure itself, but in ineffective treatment due to imprecise patient selection. Among patients with non-obstructive azoospermia, approximately 30%–50% may face the outcome of not retrieving sperm. Undergoing surgery without clear evidence of sperm presence exposes patients to the dual risks of surgical trauma and financial loss. It is recommended that all patients complete tests for FSH, inhibin B, chromosome karyotype, and Y chromosome microdeletion before surgery, and thoroughly discuss individualized surgical strategies with their reproductive physician. Reproductive centers in Georgia typically provide a written risk disclosure form before surgery; patients should read it carefully and keep a copy.